Advertisement

Annals of Hematology

, Volume 94, Issue 7, pp 1185–1193 | Cite as

Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML)

  • Su Kyung Jung
  • Ji Sun Paik
  • Seung-Eun Jung
  • Gyeongsin Park
  • Byung-Ock Choi
  • Jin Kyoung Oh
  • Yong Gyu Park
  • Suk Woo YangEmail author
  • Seok-Goo ChoEmail author
Original Article

Abstract

Ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) has been recognized as most common primary orbital malignancy. However, little was known about the response criteria for OAML. Our aim was to suggest response criteria for nonconjunctival OAML; the response evaluation of which using the conventional response criteria is inappropriate. A retrospective chart review of 34 eyes from 30 patients diagnosed with nonconjunctival OAML was conducted, focusing on the change in tumor size based on linear bi-dimensional and three-dimensional methods in magnetic resonance imaging (MRI) of the orbit. The maximum tumor response period of each case was investigated, and the expected optimal response period was calculated using regression analysis. In 30 evaluable patients, the median time taken for the maximum tumor response was 6 months (range, 3–18). More than 75 % of patients attained maximal tumor response in 6 months after initial therapy for follow-up period, the median value of which was 30 months (range, 15–77). Based on the regression analysis, it took 4.7 months for the maximum diameter (2r) of tumor to decrease by 50 % of initial lesion size. We cautiously suggest that optimal response could be defined as 50 % reduction of the maximum diameter in 6 months since the treatment was initiated, and that only observation without additional therapy is enough for nonconjunctival OAML, if optimal response is achieved.

Keywords

Marginal zone B cell lymphoma Ocular adnexal MALT lymphoma Response criteria Chemotherapy Radiotherapy 

Notes

Conflict of interest

None of the authors has financial or proprietary interests in any material or method mentioned in this study.

References

  1. 1.
    Bairey O, Kremer I, Rakowsky E, Hadar H, Shaklai M (1994) Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma. Cancer 73:2395–2399CrossRefPubMedGoogle Scholar
  2. 2.
    Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H (2004) Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 242:130–145. doi: 10.1007/s00417-003-0831-5 CrossRefPubMedGoogle Scholar
  3. 3.
    Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL (2006) Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 108:1451–1460. doi: 10.1182/blood-2006-02-005017 CrossRefPubMedGoogle Scholar
  4. 4.
    Esmaeli B, Murray JL, Ahmadi MA, Naderi A, Singh S, Romaguera J, White CA, McLaughlin P (2002) Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 120:1225–1227CrossRefPubMedGoogle Scholar
  5. 5.
    Isaacson PG, Chott A, Nakumura S, Müller-Hermelink HK, Harris NL, Swerdlow SH (2008) Extranodal marginal cell lymphoma of mucosa-associated tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 214–217Google Scholar
  6. 6.
    Jakobiec FA (2008) Ocular adnexal lymphoid tumors: progress in need of clarification. Am J Ophthalmol 145:941–950. doi: 10.1016/j.ajo.2008.03.013 CrossRefPubMedGoogle Scholar
  7. 7.
    Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N, Lightman S, Moseley I, Norton A (2000) Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 84:907–913. doi: 10.1136/bjo.84.8.907 CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Shields JA, Shields CL, Scartozzi R (2004) Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1. Ophthalmology 111:997–1008. doi: 10.1016/j.ophtha.2003.01.002 CrossRefPubMedGoogle Scholar
  9. 9.
    Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B (2007) Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging 38:319–325PubMedGoogle Scholar
  10. 10.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586. doi: 10.1200/JCO.2006.09.2403 CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson TE, Tse DT, Byrne GE Jr, Restrepo A, Whitcomb CC, Voigt W, Benedetto P, Curtin V (1999) Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg 15:171–179CrossRefPubMedGoogle Scholar
  12. 12.
    Martinet S, Ozsahin M, Belkacémi Y, Landmann C, Poortmans P, Oehlere C, Scandolaro L, Krengli M, Maingon P, Miralbell R, Studer G, Chauvet B, Marnitz S, Zouhair A, Mirimanoff RO (2003) Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 55:892–898. doi: 10.1016/S0360-3016(02)04159-7 CrossRefPubMedGoogle Scholar
  13. 13.
    Hasegawa M, Kojima M, Shioya M, Tamaki Y, Saitoh J, Sakurai H, Kitamoto Y, Suzuki Y, Niibe H, Nakano T (2003) Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 57:172–176. doi: 10.1016/S0360-3016(03)00506-6 CrossRefPubMedGoogle Scholar
  14. 14.
    Paik JS, Cho WK, Lee SE, Choi BO, Jung SE, Park GS, Kim SH, Yang SW, Cho SG (2012) Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Ann Hematol 91:1393–1401. doi: 10.1007/s00277-012-1469-3 CrossRefPubMedGoogle Scholar
  15. 15.
    Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21:4157–4164. doi: 10.1200/JCO.2003.06.085 CrossRefPubMedGoogle Scholar
  16. 16.
    Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M (2003) Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer 97:2236–2241. doi: 10.1002/cncr.11317 CrossRefPubMedGoogle Scholar
  17. 17.
    James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523–528CrossRefPubMedGoogle Scholar
  18. 18.
    Padhani AR, Ollivier L (2001) The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 74:983–986CrossRefPubMedGoogle Scholar
  19. 19.
    Kiesewetter B, Lukas J, Kuchar A, Mayerhoefer ME, Streubel B, Lagler H, Mullauer L, Wohrer S, Fischbach J, Raderer M (2014) Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients. PLoS One 9:e104004CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Kagami Y, Maeshima A, Matsuno Y, Tobinai K (2006) Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135–140CrossRefPubMedGoogle Scholar
  21. 21.
    Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B (2007) Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 125:1663–1667. doi: 10.1001/archopht.125.12.1663 CrossRefPubMedGoogle Scholar
  22. 22.
    Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, Park KS, Kang CS, Kim SH, Yang SW, Cho SG (2011) Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol 86:262–266. doi: 10.1002/ajh.21963 CrossRefPubMedGoogle Scholar
  23. 23.
    Lim SH, Kang M, Son J (2011) Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type of the ocular adnexa: retrospective single institution review of 95 patients. Indian J Ophthalmol 59:273–277. doi: 10.4103/0301-4738.81993 CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, Chott A (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 11:3349–3352. doi: 10.1158/1078-0432.CCR-04-2282 CrossRefPubMedGoogle Scholar
  25. 25.
    Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN, Moseley I, Wright JE (2003) Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye (Lond) 17:809–820. doi: 10.1038/sj.eye.6700379 CrossRefGoogle Scholar
  26. 26.
    Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B (2007) Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 110:809–815CrossRefPubMedGoogle Scholar
  27. 27.
    Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalban C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R (2012) Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 30:2988–2994CrossRefPubMedGoogle Scholar
  28. 28.
    Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J (2006) Non-Hodgkin’s lymphoma. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 4:258–310Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Su Kyung Jung
    • 1
  • Ji Sun Paik
    • 1
  • Seung-Eun Jung
    • 2
  • Gyeongsin Park
    • 3
  • Byung-Ock Choi
    • 4
  • Jin Kyoung Oh
    • 5
  • Yong Gyu Park
    • 6
  • Suk Woo Yang
    • 1
    Email author
  • Seok-Goo Cho
    • 7
    Email author
  1. 1.Department of Ophthalmology and Visual Science, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  2. 2.Department of Radiology, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  3. 3.Department of Pathology, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  4. 4.Department of Radiation Oncology, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  5. 5.Department of Nuclear Medicine, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  6. 6.Department of Medical Life Science, Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  7. 7.Department of Hematology, Catholic BMT Center, Catholic University Lymphoma Group (CULG), Seoul St. Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea

Personalised recommendations